HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical response to bevacizumab in schwannomatosis.

AuthorsJaishri Blakeley, Karisa C Schreck, D Gareth Evans, Bruce R Korf, David Zagzag, Matthias A Karajannis, Amanda L Bergner, Allan J Belzberg
JournalNeurology (Neurology) Vol. 83 Issue 21 Pg. 1986-7 (Nov 18 2014) ISSN: 1526-632X [Electronic] United States
PMID25339217 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Bevacizumab
  • Humans
  • Male
  • Neurilemmoma (diagnosis, drug therapy)
  • Neurofibromatoses (diagnosis, drug therapy)
  • Skin Neoplasms (diagnosis, drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: